blebbistatinKD025Y-27632rh-TGFβSkin fibrosissystemic sclerosis (SSc)SSc
…blasts stimulated with rh- TGFβ (n=10) using the NMII inhibitor blebbistatin, the pan-ROCK inhibitor Y-27632, and the ROCK2-selective inhibi…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 601–660 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
Sulfasalazine6Tisagenlecleucel6Zonisamide6erlotinib6hydromorphone6oxcarbazepine6Botulinum Toxin A6Calcineurin inhibitors6IL-76MMAE6PD-1 inhibitors6PLEX6Saline6Tezacaftor6abiraterone6anticoagulant6antihypertensive medications6dexketoprofen6oral steroids6phenytoin6sodium bicarbonate6Baclofen6Fluoroquinolone6Itraconazole6PPI6PRAME6Rapamycin6antiseizure medications6mephedrone6n-butyl cyanoacrylate6renin-angiotensin system inhibitors6Beta blocker6Entecavir6Oral corticosteroids6Valganciclovir6anti-seizure medications6cabotegravir/rilpivirine6citalopram6dextran sulfate sodium6penicillins6stimulants6teicoplanin6HRT5Treprostinil5Glimepiride5Orlistat5NKTR-2555Emicizumab5Efgartigimod5Sarilumab5Etrasimod5CAB-LA5D-Dimer5GDF-155TMZ5TAF5Darolutamide5ESPB5Marijuana53TC5
Articles mentioning drugs
10,506 articles · page 111 of 876Glabrescione BShhSonic Hedgehog
…nalysis of HUVEC and HMDECs treated with Shh, TGFβ or TGFβ plus Glabrescione B for 5 days showed 408 DEGs shared by TGFβ and Shh. Reactome enr…
tocilizumabmycophenolate mofetilrituximababataceptABATCZRTXcyclophosphamideazathioprinemethotrexate+4 more
…analyze long term outcome of patients with SSc-ILD treated with tocilizumab (TCZ), rituximab (RTX), and abatacept (ABA) which became availa…
P.211 Ruxolitinib therapy in pansclerotic morphea refractory to autologous stem-cell transplantation
ruxolitinibMycophenolate mofetilcyclophosphamiderituximababatacepttocilizumabmethotrexatePansclerotic morphea (PSM)
… kinase (JAK) – STAT signalling in PSM pathogenesis, suggesting ruxolitinib, a JAK 1/2 inhibitor, as potential therapeutic option [N Engl J…
efgartigimodrecombinant human hyaluronidase PH20rHuPH20PH20 SCHealth Assessment QuestionnaireSystemic SclerosisSystemic sclerosis (SSc)NCT06655155interstitial lung disease
…SSc will be randomized 2:1 to receive weekly administrations of efgartigimod or placebo PH20 SC (coformulated with recombinant human hyaluro…
rituximabmethotrexatemycophenolatemyocphenolatecyclophosphamideHealth Assessment QuestionnaireVisual Analogue Scalesystemic sclerosis (SSc)European Scleroderma Study GroupSt George's Respiratory Questionnaire+1 more
…SF-36).Conclusions These findings suggest that long-term use of rituximab provides sustained clinical benefit in patients with progressiv…
tofacitinibcyclophosphamiderituximabmethotrexatelcSSc
…slowing lung function decline in lcSSc. In addition, a trial of tofacitinib with 40 (61%) lcSSc patients showed that this drug was more eff…
PM-Scl75PM-Scl100Ro52Scleromyositisdermatomyositissystemic sclerosisIIMsystemic sclerosis-relatedSSc-polymyositisuniversity hospital+1 more
… are limited. Our study aimed to evaluate changes in PM-Scl100, PM-Scl75, and anti-Ku antibody positivity before and during the pandemic…
TirofibanNCT04751708Acute basilar artery occlusion (BAO)EVT
…; P=0.012 for stroke etiology×tirofiban interaction).Conclusion Tirofiban may be associated with favorable outcomes in non-AS BAO without…
baricitinibmethotrexateMTXUAundifferentiated arthritisRheumatoid Arthritissymptomatic therapy
…ty over 3 months compared with NSAIDs, with the improvement for baricitinib reaching statistical significance. Over 12 months, disease acti…
PegenzileukincemiplimabpembrolizumabMMcutaneous squamous cell carcinomaCSCC
…ombinations in patients with MM (Cohort A) and CSCC (Cohort B). Pegenzileukin was given at two dose levels (16 µg/kg: Cohort A1 and B1 and 24…